ASLAN Pharmaceuticals announces $18m private placement

The financing closed on 25 February.

ASLAN Pharmaceuticals has entered into a securities purchase agreement to raise gross proceeds of $18m, resulting from the sale of its ordinary shares through a private placement to new institutional investors, Vivo Capital and Surveyor Capital.

The clinical-stage immunology focused biopharmaceutical company will issue an aggregate of 25,568,180 ordinary shares, equivalent to 5,113,636 American Depositary Shares (ADSs), at an equivalent price of $3.52 per ADS, equal to the last closing price of the company’s ADSs.

According to ASLAN Pharmaceuticals CEO Dr. Carl Firth, the additional resources from the private placement will fund their ongoing study of ASLAN004 in atopic dermatitis in early March and look towards initiating the company’s phase 2b program later in 2021.

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia